NCT00110487View on ClinicalTrials.gov

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

December 31, 2006

Conditions

Endometriosis

Interventions

DRUG

ERB-041

Trial Locations (46)

20706

Lanham

20707

Laurel

23298

Richmond

28209

Charlotte

29605

Greenville

29651

Greer

30005

Alpharetta

30342

Atlanta

33136

Miami

33143

Miami

33180

Aventura

33437

Boynton Beach

33758

Clearwater

34471

Ocala

34652

New Port Richey

34684

Palm Harbor

34747

Celebration

44195

Cleveland

45267

Cincinnati

46601

South Bend

48201

Detroit

55318

Chaska

58104

Fargo

60005

Arlington Heights

60523

Oak Brook

60611

Chicago

60637

Chicago

61820

Champaign

63017

Chesterfield

71103

Shreveport

76104

Fort Worth

77598

Webster

80228

Lakewood

84070

Sandy City

85015

Phoenix

85710

Tucson

89104

Las Vegas

92093

La Jolla

92123

San Diego

95608

Carmichael

96001

Redding

97401

Eugene

08009

Berlin

75390-9032

Dallas

23507-1627

Norfolk

53792-6188

Madison

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00110487 - Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women | Biotech Hunter | Biotech Hunter